Taking up the matter of Novartis AG's secukinumab, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) provided developers of interleukin-17 (IL-17) blockers for psoriasis with an idea of how the agency might take the risk-benefit profile of the class.